News
Published:
Oxford Drug Design awarded £1m PACE funding to progress uUTI treatment
As part of company’s tRNA synthetase development in oncology and infections 20th February 2025, United Kingdom: Oxford Drug Design has been awarded £1m in funding to progress its uUTI (uncomplicated urinary tract infection) antibacterial programme, as announced by PACE (Pathways to
Published:
Oxford Drug Design achieves further in vivo validation of novel approach against multiple tumours
United Kingdom, 15th January 2025: Oxford Drug Design, the Oxford-based AI drug discovery company, has today announced additional in vivo validation for its first-in-class approach against cancer as the Company continues to apply its pioneering AI platform to develop novel treatments in oncology
Published:
Oxford Drug Design awarded share of £3m Cystic Fibrosis Collaborative Drug Discovery Programme
The cross-sector initiative provides funding and support to accelerate new treatments for lung infections in Cystic Fibrosis September 26th 2024, United Kingdom: Oxford Drug Design is among the first three companies to be awarded a share of a £3 million Collaborative Discovery Programme (CDP)
Published:
Oxford Drug Design announces initial in vivo validation of novel oncology therapeutic mechanism
Oxford Drug Design announces initial in vivo validation of novel oncology therapeutic mechanism Appoints oncologist Prof. Sarah Blagden to its Scientific Advisory Board United Kingdom, July 2024: Oxford Drug Design, the Oxford-based AI drug discovery company applying its pioneering AI…
Published:
Oxford Drug Design and CRUK Scotland Institute awarded MRC grant funding to advance novel cancer therapeutics discovery
Collaboration to use genetically engineered mouse models to validate a new approach to cancer therapy United Kingdom, June 4th 2024: The CRUK (Cancer Research UK) Scotland Institute and Oxford Drug Design, a biotechnology company with core expertise in AI drug discovery, have announced that
